Amphotericin B - Jina Pharmaceuticals/Intas Pharmaceuticals

Drug Profile

Amphotericin B - Jina Pharmaceuticals/Intas Pharmaceuticals

Alternative Names: Amfy; Nanosomal amphotericin B

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Intas Pharmaceuticals; Jina Pharmaceuticals
  • Class Antifungals; Macrolides
  • Mechanism of Action Cell membrane permeability enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Mycoses

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for clinical-Phase-Unknown development in Mycoses in Unknown (PO)
  • 22 Oct 2015 Intas Pharmaceuticals and Jina Pharmaceuticals collaborated in the development of Nanoaqualip™ technology
  • 27 Aug 2015 Launched in Mycoses in India (IV) before August 2015
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top